Publications dans lesquelles il/elle collabore avec Manuel Romero-Gómez (20)

2024

  1. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1056-1068

  2. Novel insights into metabolic-associated steatotic liver disease preclinical models

    Liver International, Vol. 44, Núm. 3, pp. 644-662

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Non-pharmacological treatment approach in patients with metabolic dysfunction-associated liver disease

    Comprehensive Guide to Hepatitis Advances (Elsevier), pp. 343-367

  4. Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention

    BMJ

2022

  1. Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival

    Viruses, Vol. 14, Núm. 9

  2. Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective

    Seminars in Liver Disease, Vol. 42, Núm. 4, pp. 434-445

  3. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

    Frontiers in Immunology, Vol. 12

  2. Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr−/−.Leiden mice without attenuation of steatohepatitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Dietary Approach to NAFLD

    Non-Alcoholic Fatty Liver Disease: A 360-degree Overview (Springer International Publishing), pp. 271-287

  2. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management

    Liver International, Vol. 40, Núm. S1, pp. 102-108

2019

  1. Co-03. La ldl oxidada es un biomarcador distintivo de la presencia de esteatohepatitis frente a fibrosis hepática en enfermedad hepática metabólica grasa

    Revista andaluza de patología digestiva, Vol. 42, Núm. 5, pp. 199-199

  2. Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models

    Revista Espanola de Enfermedades Digestivas, Vol. 111, Núm. 4, pp. 301-307

2018

  1. Co-21. Uso de microarns como biomarcadores no invasivos en enfermedad hepática metabólica por depósito de grasa no alcohólica

    Revista andaluza de patología digestiva, Vol. 41, Núm. 5, pp. 289-290

2017

  1. An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat “Western-type” diet in mice

    Molecular Nutrition and Food Research, Vol. 61, Núm. 3

  2. Co-12. Papel del factor de crecimiento de fibroblasto 21 (fgf21) en pacientes con eghna: Estudio genético y funcional.

    Revista andaluza de patología digestiva, Vol. 40, Núm. 5, pp. 277-277

2010

  1. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: A cohort study

    Annals of Internal Medicine, Vol. 153, Núm. 5, pp. 281-288